Abstract
Skin manifestations of systemic disorders give a clue to the organ involved and help identify the possible disease-causing injury. Skin changes of liver cirrhosis are not specific, as they may be seen in disorders not involving the liver. Thus, a constellation of skin changes along with systemic features may help us to identify the disease-causing liver cirrhosis. Pruritus is one of the most common and distressful symptoms of liver cirrhosis, severely affecting the quality of life, which further necessitates understanding cutaneous manifestations of cirrhosis. Other nonspecific cutaneous manifestations include spider telangiectasia, palmar erythema, paper money skin, xanthomas, pigmentation changes, nutritional deficiencies, hair changes, and nail changes. This review discusses the nonspecific skin manifestations associated with liver cirrhosis followed by specific cutaneous findings seen in common diseases causing liver cirrhosis, such as viral infections, biliary tract disorders, chronic alcoholism, and metabolic disorders. Early recognition of cutaneous features can help prevent or delay the development of complications and end-stage disease, decreasing morbidity and mortality.
Keywords: cirrhosis, skin changes, cutaneous manifestations
Abbreviations: bFGF, basic fibroblast growth factor; HBV, Hepatitis B Virus; HCV, Hepatitis C Virus; LPA, Lysophosphatidic acid; PAN, polyarteritis nodosa; PBC, Primary biliary cirrhosis; PCT, Porphyria Cutanea Tarda; PSC, Primary Sclerosing cholangitis; UROD, uroporphyrinogen decarboxylase; VEGF, vascular endothelial growth factor
Skin manifestations are the commonest among all extrahepatic manifestations of liver disease. They can be very subtle or very apparent and help in the early diagnosis and therapy of liver disease. Cutaneous features of liver cirrhosis may be categorized as nonspecific manifestations seen in most liver diseases and disease-specific such as blistering due to porphyria cutanea tarda and necrolytic acral erythema in Hepatitis C.1 Various conditions that can lead to liver damage and cirrhosis are mentioned in Table 1.
Table 1.
|
Nonspecific skin changes
Cirrhosis of any origin can cause common skin manifestations such as pruritus, jaundice, xerosis, nail changes, vascular changes, and hormonal changes. Estrogen-androgen imbalance secondary to cirrhosis is considered to cause palmar erythema, spider nevi, and gynecomastia, testicular atrophy, loss of secondary sexual hairs in males. Ascites lead to striae and umbilical hernia. Some common cutaneous clinical findings of cirrhosis are listed in Table 2.
Table 2.
|
Associated lesions
|
Pruritus
Pruritus is the commonest skin manifestation of liver cirrhosis and may appear before the diagnosis of liver disease. The pathophysiology of pruritus in cirrhosis is complex. Biochemicals such as histamine, substance P, bile acids, and endogenous opioids have been hypothesized to mediate itch in cirrhosis.2 Bile salts, along with other pruritogens, mediate cholestatic pruritus, but not every patient with increased bile salts or acids develop itching, and not every patient with raised levels respond to bile acid chelating agents.3 Blood levels of the μ-opioid receptor agonists methionine, enkephalin and β-endorphin are found to be raised in patients with cirrhosis. An excellent response has been observed to u-opioid receptor antagonists naltrexone in patients with obstructive jaundice.4 These findings strongly suggest an indirect role of endogenous opioids in mediating cholestatic itching, but the severity of pruritus does not correlate with the levels of bile salts or endogenous opioids.5 Lysophosphatidic acid (LPA) and autotaxin (an ectoenzyme involved in LPA production) are significantly increased in patients with cholestatic pruritus, suggesting they may be potential therapeutic targets.6 Typically, oral contraceptive pills intake in females increases autotaxin levels, and patients with bile obstruction commonly show increased pruritus during the progesterone phase of the menstrual cycle, late pregnancy, and hormone replacement therapy.7 Thus cirrhotic patients with reduced metabolism of androgens may find elevated autotaxin levels. Serum autotaxin levels have been reported to correlate with liver fibrosis. Therefore, they could be used to assess the progression of cirrhosis.8
Itching is most prominent in biliary obstructive and cholestatic diseases. It is most severe at acral sites and follows a circadian rhythm, with the maximum intensity in the evening and early night.9 Primary cutaneous lesions are not observed in cholestatic liver cirrhosis, but vigorous scratching causes secondary changes such as erosions, prurigo nodularis, and lichenification. Intractable pruritus may severely impact the quality of life. Patients may develop altered sleep patterns, cognitive symptoms, easy fatigability, and mood changes. They may feel anxious or depressed, and suicidal tendencies may develop.10 Pruritus of liver diseases is often resistant to treatment, with limited response to antihistamines. Commonly prescribed ursodeoxycholic acid in cholestatic pruritus is not of much help. Bile acid resins such as cholestyramine (in a dose of up to 4 g QID) are the first line of treatment. Other options include phototherapy, selective serotonin reuptake inhibitors, plasmapheresis, and opioid antagonists (naloxone). Rifampicin (150 mg daily that can be increased to 600 mg as per individual response to treatment) has been found to be effective, probably by enhancing the metabolism of endogenous pruritogens.11 Pruritus may disappear in end-stage liver disease, suggesting marked deterioration of liver function. K-opioid receptor agonists such as nalfurafine (2.5 μg daily) activate κ receptors that decrease endogenous opioids induced itching.12
Spider Angioma (Nevus Araneus)
A feature characteristically seen in nearly one-third of the patients with cirrhosis are spider angiomas, which have a small central arteriole resembling the body of a spider and tortuous thin radiating vessels resembling its legs. They are mostly seen on skin drained by superior vena cava. The lesion is blanchable and quickly refills when the pressure is released from the central arteriole.13 Its number correlates with the frequency of esophageal varices. Hyperestrogenemia is considered to be one of the responsible factors for the development of these vascular changes. Other biochemical substances such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), substance P, and endogenous vasodilators have been implicated in the etiopathogenesis of spider telangiectasias.14 Multiple spider angiomas are typical of chronic liver disease with a specificity of 95% and act as a clinical marker for esophageal varices and hepatopulmonary syndrome.15 The nevi may disappear postliver transplant in patients with cirrhosis. It may also be noted in patients with rheumatoid arthritis, thyrotoxicosis, pregnancy, and severe malnutrition (Figure 1).16
Palmar Erythema
Palmar erythema or liver palms is regarded as blanchable reddish discoloration of the palms, which may also involve the dorsal aspect of hands, fingertips, nail bed, and rarely soles of the feet. It is most predominant on the hypothenar eminences.17 Almost 23% of people with liver cirrhosis develop palmar erythema. It results from abnormal serum estradiol levels that activate the enzyme nitric oxide synthase to produce nitric oxide and induce vasodilation. It may also be seen in pregnancy, rheumatoid arthritis, diabetes, thyrotoxicosis, brain tumors, and liver diseases such as Wilson’s disease and hereditary hemochromatosis. Drugs like topiramate, albuterol, amiodarone gemfibrozil, and cholestyramine are known to cause palmar erythema. External causes such as smoking, alcoholism, and mercury poisoning also cause palmar erythema (Figure 2).18
Xanthelasma
Dyslipidemia is often a feature of cholestatic liver diseases. It presents as soft, yellow asymptomatic papules, plaques or nodules and may affect any body site. Primary biliary cirrhosis (PBC) is commonly associated with dyslipidemia and manifests as planar, tuberous, and tendinous xanthomas (Figure 3). Xanthoma striatum palmare is another finding reported in patients with PBC with hypercholesterolemia, which presents as multiple yellowish plaques over the creases of palms. Recurrent trauma increases vessels’ permeability, resulting in the seepage of lipids through these damaged vessel walls and deposition of lipids in pressure areas of the palm.
Jaundice and Pigmentary Alterations
Jaundice is the yellow pigmentation of skin, sclera, and mucous membranes resulting from the deposition of bilirubin and its metabolites in these tissues. Bilirubin levels beyond 2–2.5 mg/dL lead to clinically apparent jaundice. Blotchy or diffuse mud-grey pigmentation over the photo exposed areas may be noted in patients with cirrhosis, accentuated over the areola, palmar creases, perioral and periorbital areas. Melanosis is often seen in PBC and manifests early in the disease. Hemosiderin deposition leads to increased melanin synthesis, causing metallic brown pigmentation of skin in patients of hemochromatosis.19
Hair and Nail Changes
Patients with cirrhosis have thinning and partial loss of hairs. Males develop a female pattern of body hairs, especially pubic hairs, due to elevated estrogen levels. Nail changes in cirrhosis are nonspecific. Almost 15% of patients develop clubbing as a result of dilated digital arteriovenous anastomosis and increased blood flow. Other findings include thickening, longitudinal ridging, white transverse bands parallel to lunula (Muehrke’s bands), watch glass deformity, flattened brittle nails, or koilonychia due to micronutrient deficiency. In advanced cirrhosis, patients develop vascular nail bed changes secondary to overgrowth of connective tissue and present with proximal ground-glass opacification with a distal pink-brown color known as terry’s nails or leukonychia (Figure 4).20 In Wilson’s disease, the lunula turns blue and is named the Azure lunula. Spoon-shaped nails are seen in patients with hemochromatosis-induced cirrhosis. Hypertrophic osteopathy and splinter hemorrhages have been described in patients with cirrhosis.21
Mucosal changes - Patients with cirrhosis have decreased immunity and micronutrient deficiency. As a result, they commonly develop oral infections such as herpes and candidiasis. Angular cheilitis, aphthous ulcers, atrophic glossitis, mucosal hyperpigmentation, fissured tongue, and gingival hypertrophy can also be seen. Diuretic administration decreases the saliva causing dryness of the mouth and prone to decaying of the tooth. Those with viral hepatitis and cirrhosis develop leukoplakia, melanoplakia, lichen planus.22
Bleeding and clotting defects
Cutaneous bleeding in the form of purpura and mucosal bleeding such as epistaxis and gingival bleeding may be noted in cirrhosis (Figure 5). Those with portal hypertension develop collaterals appearing as coiled varicose veins over the abdomen. The dilated radiating pattern of veins around the umbilicus is known as caput medusae or palm tree sign (Figure 6). Diffusely scattered tiny telangiectatic vessels resembling the silk threads of dollar bill are referred to as paper money skin.23
Other nonspecific changes
Other vascular findings include corkscrew scleral vessels and bier spots.19 Bier spots are small irregular hypopigmented patches present commonly over arms and legs; they are considered an outcome of venous stasis and disappear on blanching.24
Nutritional deficiencies
The parenchyma of the cirrhotic liver is not able to store or metabolize micronutrients. Malabsorption secondary to steatorrhea further leads to decreased uptake of micronutrients. Table 3 enlists the mucocutaneous manifestation of micronutrient deficiency seen in liver cirrhosis.25
Table 3.
Vitamin deficiency | Mucocutaneous manifestation |
---|---|
Vitamin A | Xerosis Deep skin fissures (dermomalacia) Follicular hyperkeratosis (phrynoderma) Xerophthalmia |
Vitamin D | Alopecia |
Vitamin E | Follicular hyperkeratosis |
Vitamin K | Purpura Ecchymosis Gingival bleeding |
Vitamin C | Follicular hyperkeratosis Perifollicular hemorrhages Stomatitis, epistaxis, bleeding gums (scurvy) |
Vitamin B2 (riboflavin) | Seborrheic dermatitis Stomatitis, gingivitis Conjunctivitis, corneal vascularization |
Vitamin B6 (pyridoxine) | Seborrheic dermatitis Photodermatitis Glossitis, cheilitis |
Vitamin B12 (cyanocobalamin) | Hyperpigmentation of flexures, knuckles, palms, and fingers Pigmented streaks over nails Enlarged red tongue |
Vitamin B3 (niacin) | Pellagra (dermatitis, dementia, and diarrhea) |
Biotin | Alopecia Eczema around nose and mouth Conjunctivitis |
Folic acid | Gray brown pigmentation on sun-exposed areas Cheilitis Glossitis Mucosal erosions |
Disease-specific cutaneous manifestations
Viral Hepatitis
Hepatitis B Virus (HBV) can have a nonspecific erythematous rash or a serum sickness-like condition occurring in 20–30% of patients with hepatitis. Circulating immune complexes are responsible for the rash. Approximately 20% of patients suffering from polyarteritis nodosa (PAN) have positive serology for hepatitis B, while approximately 8% of patients with acute HBV infection develop PAN that is negative for autoimmune antibodies.26 Antivirals, along with steroids, should be initiated in such cases. Similarly, 15% of patients who are Hepatitis B positive have raised Cryoglobulins levels and are mostly asymptomatic. Cryoglobulinemia may affect the cutaneous (purpura, necrotic ulcers), renal, and peripheral nervous systems. Immunofluorescence of affected skin shows deposits of IgM and C3 in the vessel wall.27 Gianotti Crosti Syndrome (papular acrodermatitis of childhood) is commonly seen with HBV infection, but after the vaccination program for hepatitis B, it is more commonly associated with other viral infections such as EBV. It presents clinically as small umbilicated papules affecting the limbs, buttocks, and cheeks. It is a self-resolving dermatosis with spontaneous resolution in 1–2 months and needs symptomatic treatment.28
Hepatitis C Virus (HCV) - Almost 70% of patients infected with the Hepatitis C virus develop chronic hepatitis, and 15–30% of chronic hepatitis develop liver cirrhosis. Similarly, 70% of patients with type II cryoglobulinemia (polyclonal IgG and monoclonal IgM rheumatoid factor) and a small portion of type III cryoglobulinemia (polyclonal IgG and polyclonal IgM rheumatoid factor) are HCV positive. Clinical presentation includes small vessel vasculitis commonly affecting lower extremities, acrocyanosis, livedo reticularis, glomerulonephritis, arthralgia, hepatosplenomegaly, and hypocomplementemia (Figure 7). HCV RNA has been identified from the involved organs due to cryoglobulinemia, mainly the skin and kidneys. Anti HCV therapy should be started as first-line therapy in such cases.29 Almost 5%–30% of patients with PAN are found positive for HCV infection, and they have reduced complement levels.30 There is a higher incidence of hepatitis C among patients with an erosive variant of oral lichen planus (Figure 8). A positive association of lichen planus has been found with PBC and chronic active hepatitis due to possible immune dysfunction.31,32 Porphyria Cutanea Tarda (PCT) is a blistering disorder affecting the photo-exposed areas. It is caused by the reduced activity of uroporphyrinogen decarboxylase (UROD) enzymes that can be acquired or inherited. Blisters resolve by scar formation, dyspigmentation, milia formation, and hypertrichosis. HCV positivity may range from 10% to 90%.33
Sporadic form is the most common variant, and most of them are due to alcohol intake. Therefore, patients with alcoholic liver cirrhosis are more likely to have PCT. Necrolytic acral erythema is another marker of HCV infection, which can also be seen in zinc deficiency. Blister formation along with dusky red erythema may be noted over bilateral acral areas. Dusky reddish margins clearly demarcate the lesions. Chronic lesions develop hyperkeratotic psoriasiform changes. Clinical features mimic that of necrolytic migratory erythema and pseudo glucagonoma (Figure 9).34
Seropositivity for HCV in the presence of normal serum glucagon levels helps arrive at the diagnosis. Less well-corroborated associations with HCV infection include pyoderma gangrenosum, antiphospholipid syndrome, Behçet disease, vitiligo, amyloidosis, sarcoidosis and Sjögren syndrome.35 Table 4 describes the common cutaneous findings of viral hepatitis.
Table 4.
Common for Hepatitis B > C
|
Common to both Hepatitis B and C
|
Common for Hepatitis C > B
|
Hepatitis C
|
Alcoholic liver cirrhosis
It is recognized as the most common cause of cirrhosis in India. Patients with chronic alcohol intake develop pseudo-Cushingoid features like truncal obesity, moon facies, and proximal muscle wasting. The clinical features are nonspecific, but paper money skin and Dupuytren’s contracture are considered as strong clinical markers of alcohol abuse (Figure 10).
Facial lipodystrophy is commonly seen due to reduced caloric intake in patients with chronic alcoholism. Alcohol is a known trigger for PCT and even more in patients with concomitant HCV infection. There is a defective synthesis of clotting factors and cutaneous changes such as purpura, and other nonspecific changes like spider angiomas, palmar erythema may be noted in patients with alcoholic cirrhosis. Disseminated superficial porokeratosis has been reported to be associated with alcoholic cirrhosis, which improves when liver function normalizes. Also, nutritional dermatosis may present in the form of crusted erosions over the periorificial and genital areas, glossitis, cheilitis, hair loss, and beau’s lines over nails.19
Primary biliary cirrhosis (PBC)
It is an autoimmune disorder commonly affecting middle-aged females. Almost half of the patients with PBC have cutaneous involvement as the first symptom. Features of obstructive jaundice such as severe itching, secondary excoriation, hyperpigmentation, and various cutaneous xanthomas due to dyslipidemia may be noted. The interscapular area, which is not accessible, is spared as noted in other cholestatic disorders, known as the butterfly sign. PBC has strong positivity for antimitochondrial antibodies. Other immune disorders associated include lichen planus, vitiligo, Raynaud’s disease, keratoconjunctivitis sicca, morphea, and systemic sclerosis.36
Other biliary tract diseases
Primary Sclerosing cholangitis (PSC): Almost 66% of patients with PSC develop ulcerative colitis. These patients are more prone to develop cholangiocarcinoma and colorectal carcinoma. The associated cutaneous disorders with PSC are pyoderma gangrenosum and erythema nodosum. Pyoderma gangrenosum presents mainly in the form of a severely painful ulcer with a violaceous border, and erythema nodosum occurs as erythematous painful subcutaneous nodules commonly over legs.37
Alagille syndrome is an autosomal dominant disease caused by mutations in the JAG1 (>88%) gene or the NOTCH2 gene (around 1%). It can involve multiple organ systems, and congenital biliary tract hypoplasia is a developmental anomaly in the liver. Features of cholestasis such as severe itching, raised bilirubins, and widespread xanthomas are seen.38
Metabolic disease
Hemochromatosis - It is a disease resulting from increased iron absorption and subsequent deposition in tissues and organs such as the liver, pancreas, heart, pituitary, and endocrine organs. This deposition leads to cutaneous pigmentation, diabetes, cirrhosis, and heart failure. Skin pigmentation occurs in up to 90% of patients. Greyish or bronze cutaneous pigmentation is often noted in the early course of the disease and is more profound over sun-exposed areas. Iron deposition stimulates melanocytes to produce melanin, which is further enhanced by UV-A rays. Ichthyosiform dryness of the skin, koilonychia, and loss of body hair also occur. Classic idiopathic hemochromatosis commonly affects men and becomes apparent after 40 years of age. The acquired form is seen secondary to hemosiderosis and alcohol abuse. Phlebotomy and iron chelating agents are the treatment modalities that also improve cutaneous pigmentation. Genetic screening of relatives is commonplace. The iron overload in hemochromatosis is another cause of acquired porphyria. Hence, PCT is an important clinical manifestation leading to the diagnosis of hemochromatosis.39
Wilson’s disease is an autosomal recessive disorder of copper metabolism. Progressive copper deposition in tissue such as the liver, brain, and eyes occurs. Azure lunulae (bluish nail lunulae) is one of the characteristic manifestations of the disease. Pretibial hyperpigmentation and Kayser-Fleischer rings in the corneal membrane can also be seen.40
Other metabolic causes of cirrhosis: The majority of patients with sarcoidosis involving the liver are asymptomatic. Almost 6% of these may develop cirrhosis secondary to sarcoidosis. Liver function derangement along with cutaneous lesions of sarcoidosis may be seen.41 Similarly, patients with porphyria cutanea tarda and erythropoietic protoporphyria may also involve the liver and develop chronic parenchymal liver disease and cirrhosis.42
Skin changes in liver transplant
Patients with liver transplants have compromised immunity, and the use of immunosuppressants further adds to it. They are prone to develop cutaneous infections and malignancies. Viral infections such as warts and herpes reactivation are commonly observed. Cytomegalovirus may cause vesicular eruptions, ulceration, and hemorrhagic crust formation over oral and genital mucosa. Fungal infections such as candida affect almost 20% of patients with liver transplants. Deep fungal infections such as aspergillosis, cryptococcosis, phaeohyphomycosis may develop over the skin. Bacterial infections due to Streptococcus and staphylococcus are commonly noted. Cutaneous manifestations of graft versus host disease may appear in varied presentations. Hypertrichosis, skin atrophy, xerosis, purpura, and acne are other cutaneous lesions. Porokeratosis may occur after 4–5 years of transplant. Cutaneous malignancies such as basal cell carcinoma, squamous cell carcinoma (over vulva and perineum), Kaposi’s sarcoma, and other lymphoproliferative disorders usually develop. Cutaneous lesions such as palmar erythema, spider nevi, and pruritus improve postliver transplant.43,44
Skin changes can aid in the early diagnosis of liver cirrhosis, and many of them can help us to suspect the etiological cause. Through the window of mucocutaneous manifestations, early detection of cirrhosis can help prevent or delay the development of complications and end-stage disease, improving the survival and quality of life.
Credit authorship contribution statement
Adhyatm Bhandari: Review of literature, Data curation, Writing – original draft. Rahul Mahajan: Conceptualization, Visualization, Supervision, Validation, Rewriting- Reviewing and Editing.
Conflicts of interest
The authors have none to declare.
Acknowledgment
None.
Funding
None.
References
- 1.Ghosn S.H., Kibbi A.G. Cutaneous manifestations of liver diseases. Clin Dermatol. 2008 May 1;26:274–282. doi: 10.1016/j.clindermatol.2008.02.001. [DOI] [PubMed] [Google Scholar]
- 2.Imam M.H., Gossard A.A., Sinakos E., Lindor K.D. Pathogenesis and management of pruritus in cholestatic liver disease. J Gastroenterol Hepatol. 2012 Jul;27:1150–1158. doi: 10.1111/j.1440-1746.2012.07109.x. [DOI] [PubMed] [Google Scholar]
- 3.Beuers U., Kremer A.E., Bolier R., Elferink R.P. Pruritus in cholestasis: facts and fiction. Hepatology. 2014 Jul;60:399–407. doi: 10.1002/hep.26909. [DOI] [PubMed] [Google Scholar]
- 4.Mansour-Ghanaei F., Taheri A., Froutan H., et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol: WJG. 2006 Feb 21;12:1125. doi: 10.3748/wjg.v12.i7.1125. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.De Vloo C., Nevens F. Cholestatic pruritus: an update. Acta Gastroenterol Belg. 2019 Jan 1;82:75–82. [PubMed] [Google Scholar]
- 6.Carrion A.F., Rosen J.D., Levy C. Understanding and treating pruritus in primary biliary cholangitis. Clin Liver Dis. 2018 Aug 1;22:517–532. doi: 10.1016/j.cld.2018.03.005. [DOI] [PubMed] [Google Scholar]
- 7.Düll M.M., Kremer A.E. Management of chronic hepatic itch. Dermatol Clin. 2018 Jul 1;36:293–300. doi: 10.1016/j.det.2018.02.008. [DOI] [PubMed] [Google Scholar]
- 8.Joshita S., Ichikawa Y., Umemura T., et al. Serum autotaxin is a useful liver fibrosis marker in patients with chronic hepatitis B virus infection. Hepatol Res. 2018 Mar;48:275–285. doi: 10.1111/hepr.12997. [DOI] [PubMed] [Google Scholar]
- 9.Lipman Z.M., Ingrasci G., Yosipovitch G. Approach to the patient with chronic pruritus. Med. Clin. 2021 Jul 1;105:699–721. doi: 10.1016/j.mcna.2021.04.007. [DOI] [PubMed] [Google Scholar]
- 10.Oeda S., Takahashi H., Yoshida H., et al. Prevalence of pruritus in patients with chronic liver disease: a multicenter study. Hepatol Res. 2018 Feb;48:E252–E262. doi: 10.1111/hepr.12978. [DOI] [PubMed] [Google Scholar]
- 11.Düll M.M., Kremer A.E. Treatment of pruritus secondary to liver disease. Curr Gastroenterol Rep. 2019 Sep;21:1–9. doi: 10.1007/s11894-019-0713-6. [DOI] [PubMed] [Google Scholar]
- 12.Inui S. Nalfurafine hydrochloride to treat pruritus: a review. Clin Cosmet Invest Dermatol. 2015;8:249. doi: 10.2147/CCID.S55942. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Clough J., Smith P.J., Ikin N. Spider naevi. Br J Hosp Med. 2013 Jun;74(suppl 6):C86–C88. [PubMed] [Google Scholar]
- 14.Yalcin K., Ekin N., Atay A. Unusual presentations of spider angiomas. Liver Int: Off J Int Assoc Stud Liver. 2012 Nov 1;33:487. doi: 10.1111/liv.12009. [DOI] [PubMed] [Google Scholar]
- 15.Silvério A.D., Guimarães D.C., Elias L.F., Milanez E.O., Naves S. Are the spider angiomas skin markers of hepatopulmonary syndrome? Arq Gastroenterol. 2013 Jul;50:175–179. doi: 10.1590/S0004-28032013000200031. [DOI] [PubMed] [Google Scholar]
- 16.Ralli M., Candelori F., Di Stadio A., de Vincentiis M. Spider angioma of the nasal mucosa. Ear Nose Throat J. 2020 Dec 10 doi: 10.1177/0145561320980202. In press. [DOI] [PubMed] [Google Scholar]
- 17.Nautiyal A., Chopra K.B. Liver palms (Palmar erythema) Am J Med. 2010 Jul 1;123:596–597. doi: 10.1016/j.amjmed.2009.09.025. [DOI] [PubMed] [Google Scholar]
- 18.Serrao R., Zirwas M., English J.C. Palmar erythema. Am J Clin Dermatol. 2007 Dec;8:347–356. doi: 10.2165/00128071-200708060-00004. [DOI] [PubMed] [Google Scholar]
- 19.Smith K.E., Fenske N.A. Cutaneous manifestations of alcohol abuse. J Am Acad Dermatol. 2000 Jul 1;43:1–8. doi: 10.1067/mjd.2000.104512. [DOI] [PubMed] [Google Scholar]
- 20.Ramos-e-Silva M., Azevedo-e-Silva M.C., Carneiro S.C. Hair, nail, and pigment changes in major systemic disease. Clin Dermatol. 2008 May 1;26:296–305. doi: 10.1016/j.clindermatol.2007.10.019. [DOI] [PubMed] [Google Scholar]
- 21.Fawcett R.S., Linford S., Stulberg D.L. Nail abnormalities: clues to systemic disease. Am Fam Physician. 2004 Mar 15;69:1417–1424. [PubMed] [Google Scholar]
- 22.Zahed M., Bahador M., Asl M.H., Lavaee F., Azad A., Bahador A. Oro-dental health of patients with chronic hepatic failure. Int J Organ Transplant Med. 2020;11:115. [PMC free article] [PubMed] [Google Scholar]
- 23.Lotti T., D'Erme A.M. Clinical and Pathological Aspects of Skin Diseases in Endocrine, Metabolic, Nutritional and Deposition Disease. Springer; New York, NY: 2010. Alcohol abuse; pp. 115–120. [Google Scholar]
- 24.Passeron T. Atlas of Pigmentary Disorders. Adis; Cham: 2016. Non-melanic pigmentary disorders; pp. 205–248. [Google Scholar]
- 25.Dogra S., Jindal R. Cutaneous manifestations of common liver diseases. J Clin Exp Hepatol. 2011 Dec 1;1:177–184. doi: 10.1016/S0973-6883(11)60235-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Cacoub P., Terrier B. Hepatitis B-related autoimmune manifestations. Rheum Dis Clin. 2009 Feb 1;35:125–137. doi: 10.1016/j.rdc.2009.03.006. [DOI] [PubMed] [Google Scholar]
- 27.Desbois A.C., Cacoub P., Saadoun D. Cryoglobulinemia: an update in 2019. Joint Bone Spine. 2019 Nov 1;86:707–713. doi: 10.1016/j.jbspin.2019.01.016. [DOI] [PubMed] [Google Scholar]
- 28.Brandt O., Abeck D., Gianotti R., Burgdorf W. Gianotti-crosti syndrome. J Am Acad Dermatol. 2006 Jan 1;54:136–145. doi: 10.1016/j.jaad.2005.09.033. [DOI] [PubMed] [Google Scholar]
- 29.Charles E.D., Dustin L.B. Hepatitis C virus–induced cryoglobulinemia. Kidney Int. 2009 Oct 2;76:818–824. doi: 10.1038/ki.2009.247. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Soylu S., Gül Ü., Kiliç A. Cutaneous manifestations in patients positive for anti-hepatitis C virus antibodies. Acta Derm Venereol. 2007 Jan 15;87:49–53. doi: 10.2340/00015555-0186. [DOI] [PubMed] [Google Scholar]
- 31.Tong D.C., Ferguson M.M. Concurrent oral lichen planus and primary sclerosing cholangitis. Br J Dermatol. 2002 Aug;147:356–358. doi: 10.1046/j.1365-2133.2002.04773.x. [DOI] [PubMed] [Google Scholar]
- 32.Lodi G., Pellicano R., Carrozzo M. Hepatitis C virus infection and lichen planus: a systematic review with meta-analysis. Oral Dis. 2010 Oct;16:601–612. doi: 10.1111/j.1601-0825.2010.01670.x. [DOI] [PubMed] [Google Scholar]
- 33.Sastre L., To-Figueras J., Lens S., et al. Resolution of subclinical porphyria cutanea tarda after hepatitis C eradication with direct-acting anti-virals. Aliment Pharmacol Ther. 2020 May;51:968–973. doi: 10.1111/apt.15703. [DOI] [PubMed] [Google Scholar]
- 34.Raphael B.A., Dorey-Stein Z.L., Lott J., Amorosa V., Re V.L., III, Kovarik C. Low prevalence of necrolytic acral erythema in patients with chronic hepatitis C virus infection. J Am Acad Dermatol. 2012 Nov 1;67:962–968. doi: 10.1016/j.jaad.2011.11.963. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Garcovich S., Garcovich M., Capizzi R., Gasbarrini A., Zocco M.A. Cutaneous manifestations of hepatitis C in the era of new antiviral agents. World J Hepatol. 2015 Nov 28;7:2740. doi: 10.4254/wjh.v7.i27.2740. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Floreani A., Franceschet I., Cazzagon N., et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015 Jun 1;48:192–197. doi: 10.1007/s12016-014-8427-x. [DOI] [PubMed] [Google Scholar]
- 37.Dyson J.K., Beuers U., Jones D.E., Lohse A.W., Hudson M. Primary sclerosing cholangitis. Lancet. 2018 Jun 23;391:2547–2559. doi: 10.1016/S0140-6736(18)30300-3. [DOI] [PubMed] [Google Scholar]
- 38.Mitchell E., Gilbert M., Loomes K.M. Alagille syndrome. Clin Liver Dis. 2018 Nov 1;22:625–641. doi: 10.1016/j.cld.2018.06.001. [DOI] [PubMed] [Google Scholar]
- 39.Singal A.K. Porphyria cutanea tarda: recent update. Mol Genet Metabol. 2019 Nov 1;128:271–281. doi: 10.1016/j.ymgme.2019.01.004. [DOI] [PubMed] [Google Scholar]
- 40.Leal J.M., de Souza G.H., de Marsillac P.F., Gripp A.C. Skin manifestations associated with systemic diseases–Part 2. An Bras Dermatol. 2021 Sep 17;96(6):672–687. doi: 10.1016/j.abd.2021.06.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Ungprasert P., Crowson C.S., Simonetto D.A., Matteson E.L. Clinical characteristics and outcome of hepatic sarcoidosis: a population-based study 1976–2013. Am J Gastroenterol. 2017 Oct;112(10):1556–1563. doi: 10.1038/ajg.2017.231. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Singal A.K., Parker C., Bowden C., Thapar M., Liu L., McGuire B.M. Liver transplantation in the management of porphyria. Hepatology. 2014 Sep;60:1082–1089. doi: 10.1002/hep.27086. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Yadav D.K., Liang T. Dermatological disorders following liver transplantation: an update. Can J Gastroenterol Hepatol. 2019 Apr 1 doi: 10.1155/2019/9780952. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Lian B.S., Krishnamoorthy T.L., Oh C.C. Skin conditions in liver transplant recipients in a Singapore academic medical center: a retrospective cohort study. JAAD Int. 2021 Sep 1;4:70–78. doi: 10.1016/j.jdin.2021.06.002. [DOI] [PMC free article] [PubMed] [Google Scholar]